Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015:2015:607079.
doi: 10.1155/2015/607079. Epub 2015 Oct 1.

An update on renal artery denervation and its clinical impact on hypertensive disease

Aditya Bhat  1 , Ye Min Kuang  1 , Gary C H Gan  1 , David Burgess  1 , Alan Robert Denniss  1
Affiliations
Review

An update on renal artery denervation and its clinical impact on hypertensive disease

Aditya Bhat et al. Biomed Res Int. 2015.

Abstract

Hypertension is a globally prevalent condition, with a heavy clinical and economic burden. It is the predominant risk factor for premature cardiovascular and cerebrovascular disease, and is associated with a variety of clinical disorders including stroke, congestive cardiac failure, ischaemic heart disease, chronic renal failure, and peripheral arterial disease. A significant subset of hypertensive patients have resistant hypertensive disease. In this group of patients, catheter-based renal artery denervation has emerged as a potential therapy, with favourable clinical efficacy and safety in early trials. Additional benefits of this therapy are also being identified and include effects on left ventricular remodeling, cardiac performance, and symptom status in congestive cardiac failure. Utility of renal denervation for the management of resistant hypertension, however, has become controversial since the release of the Symplicity HTN-3 trial, the first large-scale blinded randomised study investigating the efficacy and safety of renal artery denervation. The aim of this paper is to evaluate the history, utility, and clinical efficacy of renal artery denervation technology, including an in-depth appraisal of the current literature and principal trials.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Symplicity catheter system.
Figure 2
Figure 2
Catheter-based renal artery denervation procedure.
Figure 3
Figure 3
EnligHTN catheter system.
See this image and copyright information in PMC

References

    1. Chobanian A. V., Bakris G. L., Black H. R., et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–2572. - PubMed
    1. Franklin S. S., Larson M. G., Khan S. A., et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103(9):1245–1249. doi: 10.1161/01.cir.103.9.1245. - DOI - PubMed
    1. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet. 2002;360(9349):1903–1913. doi: 10.1016/s0140-6736(02)11911-8. - DOI - PubMed
    1. Whitworth J. A. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. Journal of Hypertension. 2003;21(11):1983–1992. doi: 10.1097/00004872-200311000-00002. - DOI - PubMed
    1. Stamler J., Stamler R., Neaton J. D. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Archives of Internal Medicine. 1993;153(5):598–615. doi: 10.1001/archinte.1993.00410050036006. - DOI - PubMed

LinkOut - more resources